Fluidigm Corporation (FLDM) has been under a strong bear grip, hence the stock is down -7.33% when compared to the S&P 500 in the past 4 weeks. However, in the near-term, buying emerged at lower levels and the stock has outperformed the S&P 500 by 2.37% in the past 1 week. The stock has risen by 2.33% in the past week indicating that the buyers are active at lower levels, but the stock is down -6.97% in the past 4 weeks.
Fluidigm Corporation is up 6.47% in the last 3-month period. Year-to-Date the stock performance stands at -14.8%. The stock has recorded a 20-day Moving Average of 4.94% and the 50-Day Moving Average is 4.62%.
Fluidigm Corporation (NASDAQ:FLDM): The stock opened at $9.22 on Friday but the bulls could not build on the opening and the stock topped out at $9.26 for the day. The stock traded down to $9.00 during the day, due to lack of any buying support eventually closed down at $9.21 with a loss of -0.54% for the day. The stock had closed at $9.26 on the previous day. The total traded volume was 160,921 shares.
Fluidigm Corporation creates, manufactures and market technologies and life science tools focused on the exploration and analysis of single cells, as well as the industrial application of genomics, based upon the Companys core microfluidics and mass cytometry technologies. The Company also offers instruments and consumables to academic institutions, clinical laboratories, pharmaceutical, biotechnology and agricultural biotechnology (Ag-Bio) companies. The Company sells technologies and life-science tools, including analytical and preparatory systems for genomic and proteomic analysis, and consumables, including Integrated Fluidic Circuits (IFCs), assays, and reagents. The Companys products include C1 Single-Cell Auto Prep System; Access Array System; Biomark HD System; EP1 System; CyTOF 2 System; IFCs include C1 IFCs; Access Array IFC; Dynamic Array IFCs; Digital Array IFCs; Flex Six IFC; Access Array Target-Specific Primers, and Maxpar Reagents, among others.